Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Clinical Center for Diabetes; Shanghai Diabetes Institute; Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, 200233, China.
Cardiovasc Diabetol. 2020 Mar 28;19(1):40. doi: 10.1186/s12933-020-01020-9.
Clinical and basic investigations have indicated a significant association between circulating growth differentiation factor 15 (GDF15) and cardiovascular disease; however, the relationship between GDF15 and lower extremity atherosclerotic disease (LEAD) has been less studied. The present study aimed to explore the association between GDF15 and LEAD in Chinese patients with type 2 diabetes mellitus (T2DM). Considering that obesity is an important factor associated with circulating GDF15 levels, whether the relationship between serum GDF15 levels and LEAD is affected by body mass index (BMI) was also analysed.
A total of 376 hospitalized T2DM patients were enrolled (161 with LEAD and 215 without LEAD). A sandwich enzyme-linked immunosorbent assay was used to detect the serum GDF15 levels. The femoral intima-media thickness (F-IMT) and LEAD were assessed by ultrasonography.
Patients with LEAD had significantly higher serum GDF15 levels than those without LEAD, regardless of whether their BMI was < 25 kg/m or ≥ 25 kg/m (both P < 0.05). Serum GDF15 levels were independently positively related to the F-IMT (standardized β = 0.162, P = 0.002). After adjusting for confounding factors, per 1-standard deviation (SD) increase in the serum GDF15 levels was significantly related to an approximately 1.4-fold increased risk of LEAD in the total population (P < 0.05). Regardless of whether the BMI was < 25 kg/m or ≥ 25 kg/m, this association remained significant, with approximately 1.6- and 1.4-fold increased risks of LEAD, respectively (both P < 0.05).
High serum GDF15 levels were significantly correlated with an increased risk of LEAD in T2DM patients, and this relationship was independent of BMI.
临床和基础研究表明,循环生长分化因子 15(GDF15)与心血管疾病之间存在显著关联;然而,GDF15 与下肢动脉粥样硬化性疾病(LEAD)之间的关系研究较少。本研究旨在探讨中国 2 型糖尿病(T2DM)患者中 GDF15 与 LEAD 之间的关系。鉴于肥胖是影响循环 GDF15 水平的重要因素,还分析了血清 GDF15 水平与 LEAD 之间的关系是否受体重指数(BMI)的影响。
共纳入 376 例住院 T2DM 患者(LEAD 组 161 例,无 LEAD 组 215 例)。采用夹心酶联免疫吸附法检测血清 GDF15 水平。超声评估股内中膜厚度(F-IMT)和 LEAD。
无论 BMI 是否<25 kg/m2 或≥25 kg/m2(均 P<0.05),LEAD 患者的血清 GDF15 水平均显著高于无 LEAD 患者。血清 GDF15 水平与 F-IMT 呈独立正相关(标准化β=0.162,P=0.002)。调整混杂因素后,血清 GDF15 水平每增加 1 个标准差,总体人群 LEAD 的风险增加约 1.4 倍(P<0.05)。无论 BMI 是否<25 kg/m2 或≥25 kg/m2,这种关联仍然显著,LEAD 的风险分别增加约 1.6 倍和 1.4 倍(均 P<0.05)。
高血清 GDF15 水平与 T2DM 患者 LEAD 的风险增加显著相关,且这种关系独立于 BMI。